|
|
 Previous Article | Table of Contents | Next Article 
Total body irradiation and high-dose etoposide: a new preparatory regimen
for bone marrow transplantation in patients with advanced hematologic
malignancies [published erratum appears in Blood 1987 Jun;69(6):1789]
KG Blume, SJ Forman, MR O'Donnell, JH Doroshow, RA Krance, AP Nademanee, DS Snyder, GM Schmidt, JL Fahey and GE Metter
In a phase I/II study, 47 patients (median age, 24 years) with hematologic
malignancies (33 patients with acute leukemia not in first remission and 14
patients with other advanced malignant hematologic disorders) were treated
with total body irradiation and high doses of etoposide (VP16-213) followed
by bone marrow transplantation. At the time of analysis, 21 patients were
alive, and 19 of them were in continued complete remission for 101 days to
greater than 40 months (median, 12 months). The actuarial disease-free
survival rate of the 33 acute leukemia patients is 43% (2 SEM, 18%) and the
actuarial relapse rate is 32% (2 SEM, 20%). Five of the 14 patients with
the other hematologic malignancies are alive, and four of them continue to
be free of disease for 8 to 27 months. Pharmacokinetic studies established
a strong correlation between the administered drug doses and their plasma
levels and also demonstrated complete drug clearance prior to marrow
grafting. An etoposide dose of 60 mg/kg body weight was found to be the
maximum tolerated dose. This new preparatory regimen was well tolerated and
was not associated with specific acute or long-term regimen-related
toxicities. Our data suggest that total body irradiation with high-dose
etoposide presents a viable alternative to other preparatory regimens. The
role of this novel combination remains to be defined by future prospective
randomized trials.
Volume 69,
Issue 4,
pp. 1015-1020,
04/01/1987
Copyright © 1987 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
P. J. Stiff, C. Emmanouilides, W. I. Bensinger, T. Gentile, B. Blazar, T. C. Shea, J. Lu, J. Isitt, A. Cesano, and R. Spielberger
Palifermin Reduces Patient-Reported Mouth and Throat Soreness and Improves Patient Functioning in the Hematopoietic Stem-Cell Transplantation Setting
J. Clin. Oncol.,
November 20, 2006;
24(33):
5186 - 5193.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Lazarus, S. M. Richards, R. Chopra, M. R. Litzow, A. K. Burnett, P. H. Wiernik, I. M. Franklin, M. S. Tallman, L. Cook, G. Buck, et al.
Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993
Blood,
July 15, 2006;
108(2):
465 - 472.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Spielberger, P. Stiff, W. Bensinger, T. Gentile, D. Weisdorf, T. Kewalramani, T. Shea, S. Yanovich, K. Hansen, S. Noga, et al.
Palifermin for Oral Mucositis after Intensive Therapy for Hematologic Cancers
N. Engl. J. Med.,
December 16, 2004;
351(25):
2590 - 2598.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Sackstein, J. L. Messina, and G. J. Elfenbein
In vitro adherence of lymphocytes to dermal endothelium under shear stress: implications in pathobiology and steroid therapy of acute cutaneous GVHD
Blood,
January 15, 2003;
101(2):
771 - 778.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Auffermann-Gretzinger, I. S. Lossos, T. A. Vayntrub, W. Leong, F. C. Grumet, K. G. Blume, K. E. Stockerl-Goldstein, R. Levy, and J. A. Shizuru
Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients
Blood,
February 15, 2002;
99(4):
1442 - 1448.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Weinberg, B. R. Blazar, J. E. Wagner, E. Agura, B. J. Hill, M. Smogorzewska, R. A. Koup, M. R. Betts, R. H. Collins, and D. C. Douek
Factors affecting thymic function after allogeneic hematopoietic stem cell transplantation
Blood,
March 1, 2001;
97(5):
1458 - 1466.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X.-H. Yang, T. L. Sladek, X. Liu, B. R. Butler, C. J. Froelich, and A. D. Thor
Reconstitution of Caspase 3 Sensitizes MCF-7 Breast Cancer Cells to Doxorubicin- and Etoposide-induced Apoptosis
Cancer Res.,
January 1, 2001;
61(1):
348 - 354.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
D. Blaise, M. Kuentz, C. Fortanier, J. H. Bourhis, N. Milpied, L. Sutton, J.-P. Jouet, M. Attal, P. Bordigoni, J.-Y. Cahn, et al.
Randomized Trial of Bone Marrow Versus Lenograstim-Primed Blood Cell Allogeneic Transplantation in Patients With Early-Stage Leukemia: A Report From the Societe Francaise de Greffe de Moelle
J. Clin. Oncol.,
February 1, 2000;
18(3):
537 - 537.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Zecca, A. Pession, C. Messina, F. Bonetti, C. Favre, A. Prete, S. Cesaro, F. Porta, I. Mazzarino, G. Giorgiani, et al.
Total Body Irradiation, Thiotepa, and Cyclophosphamide as a Conditioning Regimen for Children With Acute Lymphoblastic Leukemia in First or Second Remission Undergoing Bone Marrow Transplantation With HLA-Identical Siblings
J. Clin. Oncol.,
June 1, 1999;
17(6):
1838 - 1838.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Horning, N. J. Chao, R. S. Negrin, R. T. Hoppe, G. D. Long, W. W. Hu, R. M. Wong, B. W. Brown, and K. G. Blume
High-Dose Therapy and Autologous Hematopoietic Progenitor Cell Transplantation for Recurrent or Refractory Hodgkin's Disease: Analysis of the Stanford University Results and Prognostic Indices
Blood,
February 1, 1997;
89(3):
801 - 813.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. J. Chao, G. M. Schmidt, J. C. Niland, M. D. Amylon, A. C. Dagis, G. D. Long, A. P. Nademanee, R. S. Negrin, M. R. O'Donnell, P. M. Parker, et al.
Cyclosporine, Methotrexate, and Prednisone Compared with Cyclosporine and Prednisone for Prophylaxis of Acute Graft-versus-Host Disease
N. Engl. J. Med.,
October 21, 1993;
329(17):
1225 - 1230.
[Abstract]
[Full Text]
|
|
|
|
|
